Detecting and predicting neutralization of alemtuzumab responses in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 10, 2020
- Accepted in final form April 13, 2020
- First Published June 4, 2020.
Author Disclosures
- Gauri Saxena, BSc*,
- James M. Moore, MBBS*,
- Meleri Jones, PhD,
- Gareth Pryce, PhD,
- Liaqat Ali, PhD,
- Georgia R. Leisegang, MSc,
- Vivek Vijay, MBBS,
- Samantha Loveless, PhD,
- Neil P. Robertson, MD,
- Klaus Schmierer, PhD,
- Gavin Giovannoni, PhD,
- Sharmilee Gnananpavan, PhD,
- David Baker, PhD,
- Emma C. Tallantyre, PhD* and
- Angray S. Kang, PhD*
- Gauri Saxena, BSc*,
NONE
NONE
Rod Flower Summer Scholarship awarded by QMUL
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- James M. Moore, MBBS*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Meleri Jones, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gareth Pryce, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Liaqat Ali, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National University of Medical Sciences, Rawalpindi, Pakistan.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Georgia R. Leisegang, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vivek Vijay, MBBS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Samantha Loveless, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Neil P. Robertson, MD,
Professor Robertson has served on Advisory boards for Genzyme, Roche, Novartis, Biogen, Celgene
NONE
Professor Robertson has recieved honoraria for speaking at academic meetings from Biogen and Genzyme
Professor robertson serves as an editor for the Journal of Neurology since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Neuroimmunology Fellowship Genzyme Mortality of MS Novartis pidemiology of MS, Novartis
National institute of Heath Wales, co-applicant 2015-18
NONE
Medical Research Council UK Welcome Trust
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus Schmierer, PhD,
(i) Novartis (ii) Merck KG Aa (iii) Roche
NONE
(i) Novartis, speaker honoraria (ii) Biogen, speaker honoraria (iii) Teva, speaker honoraria (iv) Merck KG Aa, speaker honoraria (v) Sanofi-Genzyme, speaker honoraria (vi) Roche, speaker honoraria
MS Reports, editorial board, since Jun 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gavin Giovannoni, PhD,
(1) AbbVie, (2)Actelion, (3) Biogen, (4) Celgene, (5)Sanofi-Genzyme, (6) Genentech, (7) GlaxoSmithKline, (8) Merck-Serono, (9) Novartis, (10) Roche and (11) Teva.
NONE
Speaker honoraria: (1) AbbVie, (2) Actelion, (3) Biogen, (4) Celgene, (5) Sanofi-Genzyme, (6) Genentech, (7) Merck-Serono, (8) Novartis, (9) Roche and (10) Teva.
(1) Multiple Sclerosis and Related Disorders, Editor since 2011
NONE
NONE
NONE
(1) AbbVie, (2) Actelion, (3) Atara Bio, (4) Biogen, (5) Celgene, (6) Sanofi-Genzyme, (7) Genentech, (8) GlaxoSmithKline, (9) Merck-Serono, (10) Novartis, (11) Roche and (12) Teva.
NONE
NONE
NONE
(1) Sanofi-Genzyme, (2) Takeda, (3) Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sharmilee Gnananpavan, PhD,
Dr Gnanapavan has received compensation for participation on scientific advisory boards for Genzyme, Novartis, Biogen and Merck.
NONE
(1)Travel and speaker honoraria from Teva, Genzyme and Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Reasearch grant from Merck in 2019.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Baker, PhD,
(1) Lundbeck (2) Merck
NONE
(1) Merck (2) Novartis (3) Roche
NONE
NONE
NONE
NONE
(1) Canbex Therapeutics (2) Japan Tobacco
NONE
NONE
NONE
NONE
NONE
The laboratory received funds for research from a academic entities unrelated to the subject of the manuscript
The laboratory received funds for research from Charities (Multiple sclerosis Society, Innovative UK/Technology Strategy Board, Diabetes UK, National Multiple Sclerosis Society), Fight for Sight for studies unrelated to the subject of the manuscript
I have recieved stock options from a commercial entity (Canbex Therapeutics) in the past to years or studies unrelated to the subject of the manuscript.
NONE
NONE
NONE
NONE
I provided consultancy to legal company acting on behalf of Teva, which was unrelated to the subject of the manuscript.
- Emma C. Tallantyre, PhD* and
I have served on scientific advisory boards for Biogen, Roche and Novartis
NONE
I have received travel expenses to attend scientific conference from Merck, Biogen and Roche.
NONE
NONE
NONE
NONE
(1) Novartis
I have received speaker fees from Takeda.
NONE
NONE
I work on research projects funded by Novartis and Genzyme.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angray S. Kang, PhD*
NONE
NONE
NONE
NONE
In one aspect, the invention provides a single polypeptide comprising a nanoluciferase domain that possesses a N-terminus and a C-terminus, a first antibody domain linked to the N-terminus by a covalent linker, and a second antibody domain linked to the C-terminus by a second covalent linker. The GloBody used in the ADA assay has been trademarked and a patent for the technology has been filed.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institute for Health Research i4i Connect Project NIHR200325 1 yr. Dates Feb 1st 2019 - 31st of January 2020. Role Collaborator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Blizard Institute (G.S., M.J., G.P., L.A., G.R.L., V.V., K.S., G.G., S.G., D.B., A.S.K.), Barts and The London School of Medicine and Dentistry, Queen Mary University of London; Division of Psychological Medicine and Clinical Neurosciences (J.M.M., S.L., N.P.R., E.C.T.), Cardiff University School of Medicine, United Kingdom; Department of Biological Sciences (L.A.), National University of Medical Sciences, Rawalpindi, Pakistan; Centre for Oral Immunobiology and Regenerative Medicine (G.R.L., A.S.K.), Institute of Dentistry, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; Clinical Board:Medicine (Neuroscience) (V.V., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust; and Welsh Neuroscience Research Tissue Bank (S.L., N.P.R.), Cardiff University, United Kingdom.
- Correspondence
Dr. Kang a.s.kang{at}qmul.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activityOnajite Kousin-Ezewu, Laura Azzopardi, Richard A. Parker et al.Neurology, May 16, 2014 -
Article
Both cladribine and alemtuzumab may effect MS via B-cell depletionDavid Baker, Samuel S. Herrod, Cesar Alvarez-Gonzalez et al.Neurology: Neuroimmunology & Neuroinflammation, June 05, 2017 -
Article
Mitigating alemtuzumab-associated autoimmunity in MSA “whack-a-mole” B-cell depletion strategyEthan Meltzer, Sarah Campbell, Benjamin Ehrenfeld et al.Neurology: Neuroimmunology & Neuroinflammation, August 07, 2020 -
Articles
Interferon β-1b–neutralizing antibodies 5 years after clinically isolated syndromeH.-P. Hartung, M.S. Freedman, C.H. Polman et al.Neurology, August 17, 2011